Evidence map›Paper›PMID 40608197›Full record

SynthesisClinical pharmacokinetics2025

Rifampicin Exposure in Tuberculosis Patients with Comorbidities in Sub-Saharan Africa: Prioritising Populations for Treatment-A Systematic Review and Meta-analysis.

Bibie Said, Yuan Pétermann, Patrick Howlett, Monia Guidi, Yann Thoma, Violet Dismas Kajogoo, Margaretha Sariko, Scott K Heysell, Jan-Willem Alffenaar, Emmanuel Mpolya and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical pharmacokinetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Two-Year Study on Swifts (Pathogens (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bibie SaidDepartment of Health and Biomedical Sciences, School of Life Sciences, Nelson Mandela African Institution of Science and Technology (NM-AIST), Arusha, Tanzania.ORCID 0000-0002-3687-6827
Yuan PétermannCenter for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Patrick HowlettNational Heart and Lung Institute, Imperial College London, Guy Scadding Building, Cale Street, London, SW3 6LY, UK.
Monia GuidiCenter for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Monia.Guidi@chuv.ch.
Yann ThomaSchool of Engineering and Management Vaud, HES-SO University of Applied Sciences and Arts Western Switzerland, 1401, Yverdon-les-Bains, Switzerland.
Violet Dismas KajogooDepartment of Clinical Trials, Tanzania Diabetes Association, P.O. Box 65201, Dar-es-salaam, Tanzania.
Margaretha SarikoKilimanjaro Clinical Research Institute, P.O. Box 2236, Moshi, Tanzania.
Scott K HeysellDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Jan-Willem AlffenaarSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Emmanuel MpolyaDepartment of Health and Biomedical Sciences, School of Life Sciences, Nelson Mandela African Institution of Science and Technology (NM-AIST), Arusha, Tanzania.
Stellah MpagamaKibong'oto Infectious Diseases Hospital, Mae, Sanya Juu, Siha Kilimanjaro, Tanzania.

Funding

Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and AdultsR01AI137080 · NIAID · UNIVERSITY OF VIRGINIA · PI Scott K Heysell, Leonid Kagan · 2018 to 2026
$6.3M
Developing research leaders at the intersection of malnutrition and tuberculosis in TanzaniaD43TW012247 · FIC · UNIVERSITY OF VIRGINIA · PI Scott K Heysell, STELLAH GEORGE MPAGAMA · 2022 to 2026
$1.4M
A global Infectious diseases framework to grow interdisciplinary researchK24AI187675 · NIAID · UNIVERSITY OF VIRGINIA · PI Scott K Heysell · 2025 to 2026
$292k
FIC NIH HHS D43 TW012247NIAID NIH HHS K24 AI187675NIAID NIH HHS R01 AI137080Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung IZSTZ0_208544
6 · The paper itself

Abstract

BACKGROUND AND

objectivesEmerging evidence suggests that comorbidities like human immunodeficiency virus (HIV) infection, diabetes mellitus (DM), and malnutrition in tuberculosis (TB) patients can alter drug concentrations, thereby affecting the treatment outcomes. For these populations, personalised strategies such as therapeutic drug monitoring (TDM) may be essential. We investigated the variations of drug levels within comorbid populations and analysed the differences in patterns observed between sub-Saharan Africa (SSA) and non-SSA regions.

methodsWe performed a systematic review and meta-analysis of rifampicin drug pharmacokinetics (PK) through searches of major databases from 1980 to December 2023. A random-effects meta-analysis model using R-studio version 4.3.2 was conducted to estimate pooled serum rifampicin exposure (area under the concentration-time curve [AUC], and peak maximum concentration [C

resultsFrom 3300 articles screened, 24 studies met inclusion criteria, contributing 33 comorbidity subgroups for meta-analysis. In SSA, 14 subgroups assessed rifampicin PK in TB-HIV, 1 in TB-DM, and none in TB-malnutrition. The pooled mean C

conclusionOur results emphasise the need for individualised dosing and targeted TDM implementation among TB-HIV and TB-DM populations on rifampicin in SSA. Although all populations exhibited low C

Indexed as

Antibiotics, AntitubercularRifampinTuberculosisAfrica South of the SaharaComorbidityDiabetes MellitusDrug MonitoringHIV InfectionsHumansAntibiotics, AntitubercularRifampin

Identifiers

PMID40608197
PMCPMC12263804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.